Sinopsis
New and exciting data presented each day during the conference and address the potential impact on current clinical practice.
Episodios
-
![New and Emerging Therapies for HCL - Jae Park, MD]()
New and Emerging Therapies for HCL - Jae Park, MD
31/12/2019 Duración: 20minHairy Cell Leukemia: New and Emerging Agents
-
![Efficacy and Safety of Current Treatment Options for HCL - Jacqueline C. Barrientos, MD, MS]()
Efficacy and Safety of Current Treatment Options for HCL - Jacqueline C. Barrientos, MD, MS
31/12/2019 Duración: 17minHairy Cell Leukemia: New and Emerging Agents
-
![WM Case Discussions - Richard R. Furman, MD and Steven P. Treon, MD, PhD, FACP, FRCP]()
WM Case Discussions - Richard R. Furman, MD and Steven P. Treon, MD, PhD, FACP, FRCP
31/12/2019 Duración: 30minUnderstanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies
-
![What is New in WM? How I Treat it - Steven P. Treon, MD, PhD, FACP, FRCP]()
What is New in WM? How I Treat it - Steven P. Treon, MD, PhD, FACP, FRCP
31/12/2019 Duración: 24minUnderstanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies
-
![CLL Case Discussions - Richard R. Furman, MD Jennifer R. Brown, MD, PhD Matt S. Davids, MD, MMSc Neil E. Kay, MD Kanti R. Rai, MD]()
CLL Case Discussions - Richard R. Furman, MD; Jennifer R. Brown, MD, PhD; Matt S. Davids, MD, MMSc; Neil E. Kay, MD; Kanti R. Rai, MD
31/12/2019 Duración: 49minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![Immune Function in CLL: What is Wrong and Why? - Richard R. Furman, MD Jennifer R. Brown, MD, PhD Matt S. Davids, MD, MMSc Neil E. Kay, MD Kanti R. Rai, MD]()
Immune Function in CLL: What is Wrong and Why? - Richard R. Furman, MD; Jennifer R. Brown, MD, PhD; Matt S. Davids, MD, MMSc; Neil E. Kay, MD; Kanti R. Rai, MD
31/12/2019 Duración: 30minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![Panel Discussion: Next Line Treatment in CLL - Neil E. Kay, MD]()
Panel Discussion: Next Line Treatment in CLL - Neil E. Kay, MD
31/12/2019 Duración: 10minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![Richters: Who will Get, What to Do? - Jennifer R. Brown, MD, PhD]()
Richter's: Who will Get, What to Do? - Jennifer R. Brown, MD, PhD
31/12/2019 Duración: 19minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![Treatment for BTKi Progressors - Richard R. Furman, MD]()
Treatment for BTKi Progressors - Richard R. Furman, MD
31/12/2019 Duración: 20minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![NOTCH1: The Clinical and Basic Science Behind it - Silvia Deaglio, MD, PhD]()
NOTCH1: The Clinical and Basic Science Behind it - Silvia Deaglio, MD, PhD
31/12/2019 Duración: 13minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![Update on CAR-T Cells in CLL - Thomas J. Kipps, MD, PhD]()
Update on CAR-T Cells in CLL - Thomas J. Kipps, MD, PhD
31/12/2019 Duración: 24minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![Venetoclax Resistance: Mechanisms and Treatment Options - Matthew S. Davids, MD, MMSc]()
Venetoclax Resistance: Mechanisms and Treatment Options - Matthew S. Davids, MD, MMSc
31/12/2019 Duración: 20minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![Panel Discussion: Front-line CLL Treatment - Richard R. Furman, MD Neil E. Kay, MD Jennifer A. Woyach, MD John N. Allan, MD]()
Panel Discussion: Front-line CLL Treatment - Richard R. Furman, MD; Neil E. Kay, MD; Jennifer A. Woyach, MD; John N. Allan, MD
31/12/2019 Duración: 04minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![Combination of Novel Agents: Is this the Final Answer? - John N. Allan, MD]()
Combination of Novel Agents: Is this the Final Answer? - John N. Allan, MD
31/12/2019 Duración: 24minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![Novel Agents in Elderly CLL Patients: Should the Approach be Different? - Jennifer A Woyach, MD]()
Novel Agents in Elderly CLL Patients: Should the Approach be Different? - Jennifer A Woyach, MD
31/12/2019 Duración: 20minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![Chemotherapy vs Novel Agents in Young CLL Patients: Is There Still a Role for Chemotherapy? - Neil E. Kay, MD]()
Chemotherapy vs Novel Agents in Young CLL Patients: Is There Still a Role for Chemotherapy? - Neil E. Kay, MD
31/12/2019 Duración: 16minPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease
-
![Atopic Dermatitis Patients - Adults (Moderate-Severe Disease) - Eric L. Simpson, MD, MCR]()
Atopic Dermatitis Patients - Adults (Moderate-Severe Disease) - Eric L. Simpson, MD, MCR
20/12/2019 Duración: 35minAtopic Dermatitis: Real-World Strategies to Improve Outcomes
-
![Atopic Dermatitis Patients - Adults (Mild-Moderate Disease) - Eric L. Simpson, MD, MCR]()
Atopic Dermatitis Patients - Adults (Mild-Moderate Disease) - Eric L. Simpson, MD, MCR
20/12/2019 Duración: 35minAtopic Dermatitis: Real-World Strategies to Improve Outcomes
-
![Atopic Dermatitis Patients - Ages 6-18 (Moderate-Severe Disease) - Lawrence Eichenfield, MD]()
Atopic Dermatitis Patients - Ages 6-18 (Moderate-Severe Disease) - Lawrence Eichenfield, MD
20/12/2019 Duración: 39minAtopic Dermatitis: Real-World Strategies to Improve Outcomes
-
![Atopic Dermatitis Patients - Ages 6-18 (Mild-Moderate Disease) - Lawrence Eichenfield, MD]()
Atopic Dermatitis Patients - Ages 6-18 (Mild-Moderate Disease) - Lawrence Eichenfield, MD
20/12/2019 Duración: 30minAtopic Dermatitis: Real-World Strategies to Improve Outcomes
